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Abstract
The study aim was to utilise multiple feature selection methods in order
to select the most important parameters from clinical patient data for high-
intensity focused ultrasound (HIFU) treatment outcome classification in uter-
ine fibroids. The study was retrospective using patient data from 66 HIFU
treatments with 89 uterine fibroids. A total of 39 features were extracted
from the patient data and 14 different filter-based feature selection meth-
ods were used to select the most informative features. The selected features
were then used in a support vector classification (SVC) model to evaluate
the performance of these parameters in predicting HIFU therapy outcome.
The therapy outcome was defined as non-perfused volume (NPV) ratio in
three classes: <30%, 30-80% or >80%. The ten most highly ranked fea-
tures in order were: fibroid diameter, subcutaneous fat thickness, fibroid
∗Corresponding Author: Visa Suomi, Department of Radiology, Turku University Hos-
pital, Kiinamyllynkatu 4-8, 20521 Turku, Finland; Email, visa.suomi@tyks.fi
Author’s pre-print submitted to arXiv October 1, 2019
ar
X
iv
:1
90
9.
13
23
3v
1 
 [p
hy
sic
s.m
ed
-p
h]
  2
9 S
ep
 20
19
volume, fibroid distance, Funaki type I, fundus location, gravidity, Funaki
type III, submucosal fibroid type and urinary symptoms. The maximum F1-
micro classification score was 0.63 using the top ten features from Mutual
Information Maximisation (MIM) and Joint Mutual Information (JMI) fea-
ture selection methods. Classification performance of HIFU therapy outcome
prediction in uterine fibroids is highly dependent on the chosen feature set
which should be determined prior using different classifiers.
c© 2019 Springer Nature Limited. This manuscript version is made
available under the CC-BY 4.0 license. https://creativecommons.org/
licenses/by/4.0/
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Introduction
Uterine fibroids (aka myomas) are benign tumours of the uterus which
are formed by the excessive growth of smooth-muscle cells in the wall of
the uterus (Stewart, 2001). They tend to be round-shaped with well-defined
boundaries and their diameter can range from 1 cm to more than 10 cm
(Walker and Pelage, 2002). These features make their diagnosis relatively
easy using ultrasound (US) or magnetic resonance imaging (MRI) (Dueholm
et al., 2002). They are commonly diagnosed in all women, but certain factors
such as age, ethnicity and heredity increase the risk (Sparic et al., 2016;
Stewart et al., 2017). Uterine fibroids occur in up to 70% of women, which
makes them the most common neoplasm affecting women (Stewart et al.,
2017).
Uterine fibroids are asymptomatic in the majority of cases, but they may
occasionally cause symptoms such as abnormal uterine bleeding, pelvic pres-
sure and pain, and reproductive dysfunction (Stewart, 2001; Zimmermann
et al., 2012). Uterine fibroids can be treated using surgical methods such
as hysterectomy or open/laparoscopic myomectomy, and in some cases hor-
monal therapy or embolisation might also be suitable. Moreover, in recent
years alternative therapy methods such as high-intensity focused ultrasound
(HIFU) have gained popularity. The benefits of HIFU therapy are its com-
plete non-invasiveness, lower costs related to patient recovery time and low
complication rate (Kim et al., 2011). However, not all patients diagnosed
with uterine fibroids are suitable candidates for HIFU treatment, which cur-
rently limits the success rate of the therapy outcome.
In clinical practice suitable patients for the HIFU therapy are typically
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screened by a radiologist together with a gynaecologist (Kim et al., 2014). For
this purpose, evaluation criteria have been formed for patient selection (Fu-
naki et al., 2009; Wei et al., 2018; Keserci and Duc, 2018), but these are
usually only based on MR images, and hence, lack more comprehensive
inclusion of clinical aspects such as the treatment history, symptoms and
patient-specific physiology. Therefore, more refined models are needed to
evaluate the suitability of patients for HIFU treatments and to predict the
treatment outcome. In order to build these prediction models, all the clini-
cal and patient parameters affecting the treatment outcome need to be first
comprehensively and rigorously determined.
The aim of this study was to utilise different filter-based feature selection
methods to identify the most important features from clinical patient data
for HIFU therapy outcome classification in uterine fibroids. More specifically,
to answer the questions:
1. Which features are the most informative in classifying the treatment
outcome?
2. What is the optimal number of features to achieve the best classification
performance?
3. Are there any specific feature selection methods that perform better in
choosing these features?
In order to answer these questions, the features chosen by the feature selec-
tion methods were used in a support vector classification (SVC) model to
evaluate their performance in treatment outcome prediction. The results of
this study identify the most prominent clinical parameters for HIFU therapy
outcome prediction in uterine fibroids, which will advance the development
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and adaptation of these models into clinical practice.
Methods
Data collection
The study was retrospective using the patient data from the uterine fi-
broid HIFU treatments conducted at the Turku University Hospital, Fin-
land, between May 2016 and January 2019. To be eligible for inclusion,
the patients had to be treated for at least one uterine fibroid with Sonal-
leve V2 (Profound Medical, Mississauga, Canada) therapy system. A total
number of 66 patients with 89 uterine fibroids were included in the study
using these criteria (see Table 1). Ethical permission for the usage of the
patient data (ETMK: 152/1801/2016) was obtained before the study from
the Ethics Committee of Hospital District of Southwest Finland. All meth-
ods were carried out in accordance with relevant guidelines and regulations
and all experimental protocols were approved by the committee. Informed
consent was obtained from all subjects and all health records collected for
the study were anonymised prior using the data. All subjects were over 18
years old.
Class labelling
The objective of the SVC model was to classify uterine fibroids according
to their predicted HIFU treatment outcome. For this purpose, the treated
uterine fibroids were divided into three classes based on their immediate post-
treatment non-perfused volume (NPV) ratios, i.e., the ratio of the ablated
volume in MR perfusion image compared to the total size of the fibroid. The
5
Table 1: Summary of study patients and treatment outcome class labels.
Category Count
Treated patients 66
Uterine fibroids 89
Non-perfused volume (NPV) ratio NPV < 30% 15
30% ≤ NPV ≤ 80% 52
80% < NPV 22
NPV ratio was selected as the class label because it can be objectively deter-
mined and has been shown to correlate with the clinical treatment outcome
of patients with uterine fibroids (Fennessy et al., 2007; Mindjuk et al., 2015).
NPV ratio of more than 80% has been shown to result in clinical success in
more than 80% of patients (Mindjuk et al., 2015). A clinical success in this
case was defined as at least 10-point reduction in the symptom severity score
after the treatment, which is considered as a common criterion for significant
symptom improvement (Stewart et al., 2006). On the other hand, NPV ratio
of less than 30% has been shown to have odds for clinical success of only one
third against those with NPV ratio of 30% or more (Fennessy et al., 2007).
Based on these thresholds, the class labels were defined as: ‘class 0’ for poor
outcome (NPV < 30%), ‘class 1’ for mediocre outcome (30% ≤ NPV ≤ 80%),
and ‘class 2’ for good outcome (80% < NPV). Each treated uterine fibroid
was categorised into one of these three classes (see Table 1).
Feature extraction
The features for therapy outcome classification were extracted manually
from pre-treatment MRI scans as well as electronic medical records stored
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Table 2: Numerical features with their mean, standard deviation (SD), minimum and
maximum values per fibroid.
Feature Mean SD Min Max
Age (years) 41.9 6.0 26 51
Weight (kg) 68.0 12.2 44 108
Height (cm) 165.4 6.2 152 178
Gravidity 1.2 1.5 0 7
Parity 0.8 1.0 0 4
Subcutaneous fat thickness (mm) 16.2 7.9 3.3 41.2
Front-back distance (mm) 141.0 17.9 89.2 173.3
Fibroid diameter (mm) 42.0 20.5 8.6 89.8
Fibroid distance (mm) 47.5 18.7 15.6 91.8
Fibroid volume (ml) 84.4 126.0 0.4 898
at the hospital. A total of 39 parameters covering different clinical aspects
of the treatments were selected as features (see Tables 2 and 3 for numerical
and categorical features, respectively). These features were selected based
on their relevance to clinical HIFU treatments, the availability of the data
in medical records and empirically observed correlations with the treatment
outcome.
Feature selection methods
A total of 14 different filter-based (i.e., independent of the classifica-
tion model) feature selection methods were used in the analysis: Chi-square
(CHI2), conditional infomax feature extraction (CIFE), conditional mutual
information maximisation (CMIM), double input symmetric relevance (DISR),
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Table 3: Categorical features with counts per fibroid.
Feature Categories Count
Ethnicity White 80
Black 6
Asian 3
Previous pregnancies Yes 50
No 39
Live births Yes 42
No 47
C-section Yes 4
No 85
Treatment history Esmya 30
Open myomectomy 4
Laparoscopic myomectomy 3
Hysteroscopic myomectomy 14
Embolisation 1
Abdominal scars Yes 24
No 65
Symptoms Bleeding 69
Pain 8
Mass 17
Urinary 11
Infertility 15
Fibroid type Intramural 54
Subserosal 8
Submucosal 31
Fibroid location Anterior 44
Posterior 38
Lateral 31
Fundus 7
Uterus position Anteverted 80
Retroverted 9
Funaki type Type I 18
Type II 66
Type III 5
8
Fisher score (FISH), F-score (FSCR), Gini index (GINI), interaction cap-
ping (ICAP), joint mutual information (JMI), mutual information feature
selection (MIFS), mutual information maximisation (MIM), minimum redun-
dancy maximum relevance (MRMR), relief (RELF) and trace ratio (TRAC).
In addition, the aggregate rankings from all feature selection methods will be
referred as TOPN. All feature selection methods are publicly available from
the scikit-feature open access repository (Li et al., 2018).
The advantage of using filter-based methods compared to wrapper and
embedded methods are that they are computationally more efficient and less
prone to overfitting (Guyon and Elisseeff, 2003). Filter-based methods rank
the features using a scoring criterion and they can be divided into univariate
or multivariate methods depending on whether their consider variables one-
by-one or together in groups, respectively. In univariate methods, the scoring
criterion only depends on the feature relevancy while the feature redundancy
is ignored. In multivariate methods, the multivariate interaction within the
features and the scoring criterion is a weighted sum of feature relevancy and
redundancy. More detailed descriptions about these methods can be found
from the reference (Li et al., 2018).
Treatment outcome classification and hyperparameter search
An overview of the data processing pipeline is presented in Figure 1. The
dataset of 89 fibroids was first read to a dataframe and was randomly divided
into training and test sets with 71:18 ratio, respectively. The splitting was
stratified which ensured that the ratio of different classes was the same in
both training and test data. Height and gravidity were the only variables
with missing values (24.7% and 7.9% of values missing, respectively) and thus
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they were imputed using their mean and mode, respectively. The imputation
values were based only on the training data in order to avoid any information
leakage from the test data.
The categorical features were one-hot encoded and all features were loga-
rithmically scaled in order to optimise the classification model performance.
Since the treatment outcome class distribution was unbalanced, class weights
were also calculated for each class in the training set in order to balance the
classifier fitting process. Once the data were pre-processed, the feature se-
lection methods (k = 1-14) were used on the training set to select the best
features (n = 2-20). These n features from the training set were then used
as inputs for the classification model.
SVC model was selected as the classification method for the problem
since it does not incorporate any built-in feature selection methods (i.e.,
embedded or wrapper) and because of its ability to perform well with small
but clean datasets. SVC is a supervised machine learning model whose basic
idea is to classify data into correct classes by using a set of hyperplanes.
These hyperplanes can either be linear or nonlinear depending on the kernel
of the model. In this study, nonlinear radial basis function (RBF) kernel
was used. The SVC model was implemented using scikit-learn (v0.20.2) in
Python (3.7.2) (Pedregosa et al., 2011).
Before starting the SVC model fitting process with the selected n features
from the training data, a set of hyperparameters were determined for grid
search (see Table 4). The aim of the grid search was to find the optimal com-
bination of hyperparameters for each set of features by iterating over all the
possible combinations of the given grid. The performance of each hyperpa-
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rameter combination was evaluated using stratified 10-fold cross-validation
on the training data and calculating a validation score (F1-micro) for each
Repeat for n features
Repeat for k 
feature selection 
methods
Test set (n features)
Training set
6) Select n 
best features
Training set (n features)
Repeat for each hyper-
parameter combination
7) Train model using
10-fold cross-validation
8) Obtain the best 
model based on 
validation scores
for prediction
9) Save final test 
score for feature 
selection method k 
using n features
5) Use feature 
selection method k
Repeat 200 times with new randomisation seed
Training set 1) Read data
2) Split into training and test sets
3) Impute missing values
4) Scale features
Test set
Figure 1: Overview of the data processing pipeline: 1) The data were read to a dataframe;
2) split into training and test sets; 3) imputed with mean or mode values based on the
training set; 4) the features were log-scaled; 5) feature selection method (k = 1-14) was
used on the training set; 6) the highest-ranking features (n = 2-20) were obtained; 7) the
n features from method k were used to train a support vector classification (SVC) model
using hyperparameter grid search with inner 10-fold cross-validation; 8) the SVC model
was refit on the whole training set using the combination of hyperparameters based on
the highest cross-validation score (F1-micro); 9) the fitted SVC model was used to classify
uterine fibroids in the test set with the same n features and the test score (F1-micro) was
saved. Steps 1-9) were repeated 200 times with a new randomisation seed.
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Table 4: Hyperparameters for grid search in support vector classification (SVC) model
fitting.
Parameter Values
Kernel RBF
C 1e-1, 1, 1e1, 1e2, 1e3, 1e4
Gamma 1e-2, 1e-1, 1, 1e1, 1e2, 1e3, 1e4
fold. The mean score over all 10 folds was then selected as the performance
metric of the given hyperparameter combination and the process was re-
peated for the next set of hyperparameters. Once all hyperparameter combi-
nations had been evaluated, the best mean score was selected as the optimal
set of hyperparameters for the given n features. The SVC model was then
refitted on the whole training set using these hyperparameters. Finally, the
fitted model was used to make predictions on the test set with the same
n features and the test score (F1-micro) was calculated based on the test
predictions as the final performance metric.
The whole process above was repeated 200 times using a new randomi-
sation seed in every iteration, which was found to ensure the stability and
repeatability of the results. All the results are thus average values over 200
iterations. The total computation time was about 10 hours using a desktop
computer with CPU processing (Intel Xeon E5-2643 v3 @ 3.40 GHz).
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Results
Feature importance and correlation
A heatmap of the median feature rankings (range 0-38 from the best to
worst) in classifying HIFU treatment outcome in uterine fibroids is shown in
Figure 2. The rankings are shown for all 39 features from the 14 different
feature selection methods. Each feature had 200 rankings per method and
their corresponding median value is presented in the map. In addition, the
aggregate median rankings from all methods (14 methods × 200 repetitions
= 2800 rankings per feature) are shown at the bottom (TOPN).
It is evident from Figure 2 that most methods (9 out of 14) are rather
unanimous about fibroid diameter being the most informative feature in
classifying the HIFU treatment outcome in terms of the immediate post-
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Figure 2: Heatmap showing the median feature rankings (range 0-38 from the best to
worst) from 14 different filter-based feature selection methods (200 rankings per feature)
in classifying HIFU treatment outcome in uterine fibroids. In addition, the median ranking
from all methods (14 methods × 200 repetitions = 2800 rankings per feature) for each
feature is shown at the bottom (TOPN).
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treatment NPV ratio. This is somewhat expected since large fibroids take
longer time to treat, and with limited treatment time windows, they cannot
always be fully ablated. Furthermore, due to their large size some parts of the
fibroid might be out of the reach of the ultrasound focal point or they might
be located behind adjacent tissue structures, such as the bowel, preventing
treatment delivery to these locations. It is also noticeable that some methods
have strong disagreement about the rankings. FISH and FSCR rank fibroid
diameter approximately in the middle (18th) while CHI2 and TRAC place
it near the end (29th and 31st, respectively).
The statistical distributions of the aggregate rankings are visualised in
the boxplot in Figure 3 which shows the features ordered by their median
rankings (i.e., TOPN in Figure 2). The boxes display the interquartile ranges
(IQR) and the median values are marked with a notch inside each box. The
whiskers show 1.5 IQR from the lower and upper quartiles and outliers are
plotted as individual points beyond the ends of the whiskers. In addition,
the pairwise Spearman’s correlation coefficients between numerical features
are shown in Figure 4.
The ten highest-ranking features organised by their aggregate median
value were: 1) fibroid diameter, 2) subcutaneous fat layer thickness, 3) fi-
broid volume, 4) fibroid distance from the skin surface, 5) Funaki type I,
6) fundus location, 7) gravidity, 8) Funaki type III, 9) submucosal fibroid
type and 10) urinary symptoms. Some of the features have relatively large
IQRs and whiskers, which indicates a certain degree of disagreement between
the methods. There are also visible outliers outside the whiskers in some of
the features. Nevertheless, it is evident that features related to the physical
14
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Figure 3: Boxplot showing the feature rankings (range 0-38 from best to worst) from 14
different filter-based feature selection methods (14 methods × 200 repetitions = 2800 rank-
ings per feature) in classifying HIFU treatment outcome in uterine fibroids. The features
are ordered by their median value based on the rankings. Boxes show the interquartile
ranges (IQR) with median values (notch) and whiskers show 1.5 IQR from the lower and
upper quartiles. Outliers are plotted as individual points beyond the ends of the whiskers.
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measures of the fibroid and patient geometry are ranked highest. It should
also be noted that Figure 3 shows the highest-ranking features from the ag-
gregate votes, and thus, they may not represent the optimal feature set for
the best treatment outcome classification performance as will be seen in the
next section.
Fibroid diameter and fibroid volume ranked first and third, respectively,
both of which indicate the size of the fibroid. It is obvious that both of these
features are also strongly correlated (see Figure 4), but diameter seems to
contain more information in terms of outcome classification when compared
to fibroid volume. As mentioned earlier, larger fibroids take longer to treat,
and hence, the treatment time constraint limits their final NPV ratio after
the treatment. Furthermore, parts of a large fibroid might also be located
outside the allowed sonication region by the system or they might be located
behind adjacent tissue structures preventing the treatment delivery.
Subcutaneous fat layer thickness ranked second overall despite of its rel-
atively large statistical dispersion. Ultrasound energy is strongly attenuated
by the subcutaneous fat layer, and thus, a thick fat layer efficiently reduces
heating efficacy of the ultrasound field. Poor heating efficacy consequently
translates to lower expected NPV ratio. Furthermore, the thickness of fat
layer affects the cooling times between sonications, which causes the total
treatment time become longer. Subcutaneous fat layer thickness is also
strongly correlated with patient weight (ranked 13th) as seen in Figure 4,
but since weight is also affected by height (ranked 15th) and muscle mass,
it is not a direct indication of the fat content per se. For this reason, sub-
cutaneous fat layer thickness contains more predictive information in this
16
case.
Fibroid distance from the skin surface was ranked fourth overall. Longer
propagation distance results in higher attenuation of the ultrasound energy,
which has fundamentally the same effect as the subcutaneous fat layer. Fi-
broid distance also adds another element to this measurement by providing
information about the intra-abdominal fat which varies significantly and is
not necessarily in correlation with the subcutaneous fat layer. Furthermore,
longer distance affects the reachability of the fibroid since the therapeutic
transducer has a fixed focal length (14 cm) from its surface. Fibroids that
are located very far back have therefore worse prospective treatment out-
come due to the combined effect of high ultrasound attenuation and limited
reachability. It should be noted that the usage of different bowel manipu-
lation techniques (Jeong et al., 2017) might affect this distance. However,
the distances in this study were measured from treatment planning images,
which should correspond to the actual distances during the treatments.
The feature quantifying the distance between the skeletal muscle and the
back-bone (i.e., front-back distance) ranked 24th. In theory, the smaller the
front-back distance the easier it is to manipulate the location of the myoma
using different gel-filling techniques. However, this parameter did not seem
contain much predictive information about the treatment outcome.
Funaki types are clinically used categories to classify the intensity of uter-
ine fibroid based on T2-weighted MR images. The fibroids are divided into
three Funaki types according to their average T2-signal intensity compared
to those of the myometrium and skeletal muscle. The high-intensity fibroids
on the T2-weighted images have been shown to represent high vascularisa-
17
tion, fluid-rich tissues or degeneration (Funaki et al., 2007), which generally
results in diminished heating efficacy. By their definition, Funaki types I (low
T2 intensity) and III (high T2 intensity) predict good and poor therapy out-
come, respectively. They were ranked fifth and eighth overall, which further
proposes their ability to contain information about the treatment outcome
in terms of the NPV ratio. Funaki type II ranked 14th, and thus, it is not
as informative predictor for treatment outcome as the other two.
Fundus location (i.e., fibroids located at the top of the uterus) was ranked
sixth which most likely relates to its good reachability during HIFU treat-
ments. This is especially true when the uterus is in anteverted position,
which is the most common case (see Table 3). Fibroids located at the top of
the uterus are typically easier to reach with the limited coverage of the ultra-
sound field, and therefore, their prospective treatment outcomes are usually
good. The other locations (lateral, anterior and posterior) do not seem to
be quite as informative with the respective rankings of 11th, 17th and 18th.
Retroverted and anteverted uterus positions ranked 22nd and 25th, respec-
tively. Anteverted position is typically more desirable for the reachability of
fibroids, but its predictive information content is slightly lower compared to
retroverted position.
Gravidity, specifying the number of pregnancies, ranked seventh overall.
It is not completely clear why this number would have predictive information
about the therapy outcome since previous/undergone pregnancies do not af-
fect the hormonal levels in women. However, it might be related to the size of
the uterus after multiple pregnancies. Another possible explanation is that
multiple pregnancies could affect the type or location of the fibroids. There
18
was also some disagreement about its ranking between different feature selec-
tion methods (i.e., relatively large IQR). In Figure 4 it is shown that gravidity
is strongly correlated with parity (i.e., the number of live births), which was
ranked only 29th overall. The same features as Boolean variables (i.e., previ-
ous pregnancies and live births) ranked 36th and 39th overall. Therefore, the
Boolean parameters are not as informative as their corresponding numerical
values.
Fibroid types are determined by their growth direction with submucosal
fibroids growing towards the uterine cavity while subserosal fibroids project
to the outside of the uterus and intramural fibroids grow within the mus-
cular uterine wall. It should be noted that these types are not mutually
exclusive and hence some fibroids might be of more than one type. Sub-
mucosal fibroids were ranked ninth overall with subserosal and intramural
fibroids ranking 32th and 33th, respectively. Submucosal fibroids are usually
also the most problematic in terms of their symptoms with heavy bleeding
and they have often been previously treated with hysteroscopic myomectomy
due to the same reason. One hypothesis might be that these previous inter-
ventions have changed the internal tissue structure of the fibroids (in terms
of vascularisation and fluid content), which also affects the therapy outcome.
In addition, previous treatments may have reduced their size considerably,
which is likely to result in better HIFU treatment outcome.
Urinary symptoms (i.e., incontinence) was ranked tenth overall. Fibroids
causing urinary symptoms are typically located adjacent to bladder, which
is a favourable location in terms of therapy efficacy. Ultrasound effectively
penetrates through bladder consisting mainly of water, and thus, the energy
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reduction due to attenuation is minimal. This allows high heating efficacy at
the target location, which often times results in high NPV ratio. The other
symptoms (infertility, mass effect, bleeding and pain) ranked 16th, 21st, 31st
and 34th, respectively, and were not considered to be as informative.
Previous treatments for uterine fibroids did not contain enough informa-
tion in estimating the treatment outcome to be ranked in top ten. Hormonal
therapy (i.e., esmya), hysteroscopic myomectomy, open myomectomy, laparo-
scopic myomectomy and embolisation ranked 12th, 26th, 30th, 35th and 38th,
respectively. It has been shown that some hormonal therapies for uterine fi-
broids change the morphological tissue properties and vascular structure of
the myoma (Crow et al., 1995; Smart et al., 2006), which would also affect
its acoustic and thermal properties.
Likewise, ethnicity did not have a lot of predictive information related
to the treatment outcome in the study population. The patient group con-
sisted of Asian, white and black populations which ranked 19th, 23rd and
27th, respectively. It is known that black people are more likely to develop
myomas (Stewart et al., 2017), which might affect the prospective treatment
outcome in terms of the size and number of fibroids. However, the large
majority of the patient group were white (see Table 3) so this result might
be somewhat biased, and thus, the importance of ethnicity was not reflected
in the results.
Previous surgeries in the abdominal area also did not have considerable
effect on the treatment outcome. The respective rankings C-section and the
presence of abdominal scars were 20th and 37th. Other abdominal interven-
tions such as laparoscopic or open myomectomy also cause scarring. Scars
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tend to heat considerably during therapeutic ultrasound treatments which
is why they are usually covered using scar tape during the therapy. The
scar tape causes part of the ultrasound energy be reflected which reduces the
heating efficacy at the target location. However, this effect did not seem to
be remarkable in terms of the treatment outcome.
Age ranked 28th overall and is known to affect the hormonal levels in
women. All women in the study were premenopausal with regular menstrual
cycle. The oestrogen and progesterone levels in blood have some cyclic vari-
ations but they do not usually differ markedly between women or change
within the fertile age range (Melmed et al., 2015). The hormonal milieu
within the fibroids may differ from that in blood circulation and be of more
importance regarding the response of the fibroid to different medical thera-
pies. The response of fibroids to hormonal stimuli may also vary depending
on the structure of the fibroid, which is something that can be assessed with
MRI. However, it should be noted that the patient population in the study
was pre-screened using MRI with fibroids initially found suitable for HIFU
treatment, thereby resulting in a more homogeneous fibroid group. Currently
there are no data on association of hormonal levels and fibroid MRI appear-
ance. Moreover, there are no data suggesting that levels of sex hormones
have an effect on the response of the fibroid to HIFU therapy, which is also
reflected in the results. Obtaining hormonal levels in fibroids would require
an invasive biopsy which is not suitable in standard clinical practice.
Classification performance
Once the most important features were determined using all the feature
selection methods, their performance in classifying the treatment outcome
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was evaluated with the SVC model. For this purpose, the number of input
features for the model was varied between 2 and 20 using the highest-ranking
features from each method. Figure 5(a) shows a heatmap of the average F1-
micro scores over 200 iterations using the specified number of highest-ranking
features from each feature selection method. In addition, the mean test scores
using the highest-ranking features from aggregate votes (see Figure 3) are
shown at the bottom (TOPN). Figure 5(b) shows the mean and dispersion of
the validation and test scores as a function of highest-ranking features from
all feature selection methods. The faded areas show the 95% confidence
intervals.
In Figure 5(a), most feature selection methods achieved relatively high
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Figure 5: (a) Heatmap showing the mean test scores (F1-micro) from support vector
classification (SVC) model in classifying HIFU treatment outcome in uterine fibroids.
The values show the mean test score from 200 repetitions using the stated number of
highest-ranking features from each feature selection method. In addition, the mean test
scores using the highest-ranking features from aggregate votes are shown at the bottom
(TOPN). (b) Lineplot showing the mean and dispersion of validation and test scores with
the number of highest-ranking features from all feature selection methods. The faded areas
show the 95% confidence intervals.
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performance scores with only two of the highest-ranking features. The best
classification performance with two features was achieved using RELF whose
mean test score was 0.61. The two highest-ranking features by their median
value from RELF were fibroid volume and subcutaneous fat layer thickness
(see Figure 2). The worst performance was achieved using GINI whose mean
test score with two features was 0.39. The two highest-ranking features
from GINI were white ethnicity and mass symptom which clearly did not
contain as much predictive information. Relatively low mean scores were
also displayed by FSCR, CHI2 and FISH whose respective test scores were
0.43, 0.44 and 0.45. All of them used Funaki type III and fundus location as
the two most important features.
From Figure 5(b) it is evident that increasing the number of features
improves the performance of the classification model. The validation and test
scores increased continuously and peaked with ten features after which the
scores stayed almost flat. The dispersions of both validation and test scores
also got smaller when the number of features increased, which is a result
of more robust classification performance. Hence, using the ten highest-
ranking features seems like the optimum amount for the best classification
performance with the SVC model.
In Figure 5(a) the best classification performance was achieved using the
ten highest-ranking features from MIM and JMI both of which achieved the
mean test score of 0.63. The ten highest-ranking features from MIM in order
were (see Figure 2): 1) fibroid diameter, 2) fibroid distance, 3) fibroid volume,
4) front-back distance, 5) subcutaneous fat layer thickness, 6) weight, 7) age,
8) height, 9) gravidity and 10-11) Funaki type III/fundus location. Likewise,
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for JMI these were: 1) fibroid diameter, 2) fibroid distance, 3) fibroid volume,
4) subcutaneous fat layer thickness, 5) front-back distance, 6-7) age/weight,
8) height, 9) anterior location and 10) gravidity. The top eight features from
both methods were the same (although not in the same order) after which
there was some discrepancy.
When using the highest-ranking features from the aggregate median rank-
ings (TOPN) in Figure 3, the performance of the classification model was ac-
tually slightly lower compared to the features chosen by some of the feature
selection methods. This is because the aggregate rankings represent the me-
dian vote from all the methods, and therefore, their performance should also
be around average. Thus, in order to achieve the best classification perfor-
mance, different feature selection methods should be evaluated individually
in order to determine their suitability for the chosen classification model. In
this study, RELF, JMI and MIM were found to be the most ideal for the
SVC model.
It should also be considered that some of these features are strongly cor-
related with each other (see Figure 4), and thus, using them at the same
time does not necessary bring any additional predictive information to the
model. Furthermore, collinearity between features might affect the predic-
tive performance of the chosen model when they are used at the same time.
For instance, fibroid diameter and fibroid volume are both indicators of the
size of the myoma and the latter is just a volumetric transformation of the
former (i.e., assuming spherical fibroid shape). Therefore, only one of these
features would be enough to bring the necessary information to the model.
In clinical setting typically only the fibroid diameter is readily available and
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thus it is preferable to the fibroid volume.
Discussion
Previous research has shown that certain physiological and MRI parame-
ters have significant statistical correlation with the HIFU treatment outcome
in uterine fibroids (Funaki et al., 2007; Mindjuk et al., 2015; Keserci and Duc,
2018). Funaki et al. (2007) divided the intensities in T2-weighted MR im-
ages of uterine fibroids into three separate classes (i.e., type I, II and III)
using threshold values based on the skeletal muscle and myometrium. It was
shown that the post-treatment NPV ratio correlated with these three classes
and that type III fibroids had significantly lower NPV ratio compared to
type I and II fibroids. Therefore, it was suggested that type I and II fibroids
were suitable candidates for HIFU treatment whereas type III fibroids were
not. Since then, this relatively simple classification method has been widely
adopted in clinical practice to evaluate the treatability of uterine fibroids.
The results in this study further suggest that at least Funaki types I and
III have predictive information related to treatment outcome. However, the
result might be slightly biased since type III fibroids were usually excluded
from the treatments. Therefore, further study of these types of fibroids and
the factors affecting their treatability should be considered in the future.
Mindjuk et al. (2015) conducted statistical univariate and multivariate
analyses on multiple clinical parameters affecting the treatment outcome in
uterine fibroids. In the univariate analysis it was found that subserosal fi-
broid location, fibroid septation, fibroid volume, T2-weighted (i.e., equal to
Funaki type) and CE-T1-weighted fat saturated signal intensities, and fibroid
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distance from spine and skin were the most significant parameters correlating
with the immediate post-treatment NPV ratio. In the multivariate analysis
the fibroid volume and T2w signal intensity were not found to be signifi-
cant factors. It was also shown that the NPV ratio is the only statistically
significant variable for predicting the risk of retreatment, and thus, it can
serve as an indicator of clinical success. In this study, subserosal fibroid loca-
tion placed only 32th in the aggregate rankings, but fibroid volume, fibroid
distance from the skin surface, and Funaki types I and III were all in top ten.
Keserci and Duc (Keserci and Duc, 2018) studied the role of MRI pa-
rameters in predicting the treatment outcome of HIFU therapy in uterine
fibroids with NPV ratio of at least 90%. It was shown with a multivariate
analysis that the thickness of the subcutaneous fat layer, T2-weighted signal
intensity ratio of fibroid to myometrium (i.e., Funaki type I/II or III) and
MRI perfusion parameters had significant correlation with the immediate
post-treatment NPV ratio of at least 90%. MRI perfusion parameters were
not included in this study, but subcutaneous fat layer thickness, and again,
Funaki types I and III were placed in top ten in the aggregate rankings.
The novelty of this study was to employ a wide selection of different
filter-based feature selection methods to evaluate the information content of
multiple clinical parameters in classifying the treatment outcome. In addi-
tion, a machine learning model (SVC) was used for the first time to take
the advantage of these features in predicting the treatment outcome in three
separate classes defined by the immediate post-treatment NPV ratio. The
results showed that it is important to select the optimal feature set in or-
der to achieve the best prediction performance with the chosen classification
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model.
Similar framework was utilised in a study by Parmar et al. (2015) who
used 14 different filter-based feature selection methods to choose radiomic
features for predicting the two-year survival rate of lung cancer patients.
In addition, they evaluated the performance of 12 classification methods
in predicting the survival rate. It was found out that for the given prob-
lem Wilcoxon feature selection method had the highest performance whereas
CHI2 and CIFE performed the worst. For classification methods, random
forest showed the highest predictive performance whereas decision tree had
the lowest. It was concluded that the choice of classification model is the
most dominant source of performance variation. In this study the best per-
forming feature selection methods were JMI and MIM while FISH and FSCR
performed the worst with ten highest-ranking features.
The algorithm pipeline used in this study was a modification of the one
used by Deist et al. (2018) who compared different classifiers in predicting
the outcome of (chemo)radiotherapy. However, they did not employ separate
filter-based feature selection methods because all the classifiers had built-
in dimensionality reduction (i.e., embedded or wrapper feature selection).
Random forest and elastic net logistic regression models yielded the highest
discriminative performance among the studied 12 datasets, but there was no
single best classifier across all datasets.
In this study only a single classification model (SVC) was used because
of its omission of built-in dimensionality reduction and robust performance
with small but clean datasets. The classification performance could poten-
tially have been further improved by using balanced classes and/or different
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classifier. However, the aim of this study was not to achieve the best possible
classification performance, but to find out the most important and informa-
tive features from the studied clinical parameters. Therefore, the results of
this study will act as an important reference for future research using dif-
ferent machine learning models in predicting HIFU treatment outcome in
uterine fibroids.
The limitations of the study include the omission quantitative perfusion
values (MRI-T1 (Keserci and Duc, 2017) or contrast-enhanced US (Wang
et al., 2016)) from the analysis, which would likely rank high in terms of
their correlation with the treatment outcome. T1-perfusion images are not
included in the standard set of images acquired in the patient screening scans,
and therefore, these values were not analysed due to the scarcity of available
data. Therefore, perfusion values should be considered in potential future
studies.
Ultimately the aim is to create a machine learning model which could
accurately predict the HIFU therapy outcome in uterine fibroids with as
few clinical parameters as possible without compromising the performance
of the model, and therefore, the inclusion of all the possible features in the
final model is neither desired nor purposeful. Furthermore, these parameters
should be easily obtainable in order to streamline the patient screening work-
flow. Lastly, the final model should be fast and simple enough to use in order
to be adopted in clinical practice. The prediction model would not replace
the radiologist or gynaecologist in the screening process, but rather would
assist the patient selection by giving a quantitative and objective estimate
of the treatment outcome based on the pre-treatment parameters.
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